Biodesix announces commercial availability of sars cov-2 neutralization antibody test

Boulder, colo.--(business wire)---- $bdsx #patientsfirst--biodesix, inc. (nasdaq: bdsx), a leading data-driven diagnostic solutions company with a focus in lung disease, today announced the broad commercial launch of a sars cov-2 neutralization antibody test (cpass™ neutralization test kit, genscript inc.). the test uses elisa technology to detect circulating neutralizing antibodies against the receptor binding domain (rbd) of the severe acute respiratory syndrome coronavirus 2 (sars-cov-2 virus) and is the first and o
BDSX Ratings Summary
BDSX Quant Ranking